Four articles. Four minutes. | Issue #4
Surgery: Intravitreal bevacizumab improves 3-year trabeculectomy survival versus placebo
Medication: Preoperative brimonidine linked to increased risk of trabeculectomy failure
Epidemiology: High myopia linked to increased risk of glaucoma and future filtering surgery
Artificial Intelligence: Natural language processing detects glaucoma follow-up lapses from clinic notes
Intravitreal Bevacizumab Improves Trabeculectomy Survival at 3 Years: Long-term Follow-up from The 'Bevacizumab in Trabeculectomy Study'.
Methods
131 patients undergoing primary or redo trabeculectomy or phaco-trabeculectomy with mitomycin C (MMC) for progressive glaucoma at one Australian referral center were randomized to single intraoperative intravitreal bevacizumab 1.25 mg/0.05 mL or balanced salt solution. The 36-month analysis assessed complete (meeting target IOP without medication) and qualified success (with medication) against individualized target IOP.
Results
Bevacizumab improved complete success (92.3% vs 71.2%, p=0.001) and qualified success (98.5% vs 89.4%, p=0.03) at 36 months. The need for glaucoma medication was also higher in the placebo cohort at 3, 6, 12, and 36 months (all P<0.01). No complications were reported in either group after 12 months.
Conclusion
In this randomized placebo-controlled trial, a single intraoperative intravitreal bevacizumab injection was associated with improved 3-year trabeculectomy survival and reduced need for topical therapy.
Our Angle
Vascular endothelial growth factor (VEGF) inhibition has been explored as a strategy to reduce early bleb fibrosis after trabeculectomy, although prior studies using subconjunctival or intracameral delivery largely failed to improve bleb survival. The three-year data from this RCT following intravitreal bevacizumab is promising, but interpretation is limited by the single-center design, mixed glaucoma phenotypes, and unresolved questions around optimal patient selection, dosing, and mechanism of action.
Medication
Topical Brimonidine Is Associated With Trabeculectomy Failure in Glaucoma Patients
Design: Retrospective observational cohort study
Journal: American Journal of Ophthalmology, June 2026
Authors: Yang et al.
Among 501 eyes undergoing primary trabeculectomy, preoperative brimonidine use was associated with nearly 3-fold higher risk of surgical failure from uncontrolled IOP, with 3-year success rates of 82% in brimonidine-exposed eyes and 93% in unexposed eyes. The findings raise concern that chronic alpha-agonist exposure may adversely affect bleb outcomes, although interpretation is limited by the retrospective single-center design, 43% loss to follow-up, non-randomized medication exposure, and lack of consistent longitudinal medication and ocular surface data.
Epidemiology
Risk of Glaucoma and Undergoing Glaucoma Surgery in Myopic and Highly Myopic Eyes: A Nationwide Population-Based Cohort Study
Design: Nationwide population-based cohort study
Journal: Ophthalmology, January 2026
Authors: Akada et al.
In a nationwide Japanese cohort of 14.2 million adults followed for 7.5 years, myopia was associated with higher risk of developing open-angle glaucoma (OAG) and requiring glaucoma surgery, with high myopia carrying nearly 3-fold greater OAG risk and 4-fold greater risk of filtering surgery compared with nonmyopia. These findings support closer long-term glaucoma surveillance in highly myopic patients, although interpretation is limited by the claims-based design and lack of detailed clinical data such as IOP, axial length, visual field, glaucoma subtype, and continuous refractive-error measurements.
Artificial Intelligence
Leveraging natural language processing to assess follow-up patterns in glaucoma care
Design: Retrospective cohort study with natural language processing algorithm validation
Journal: Ophthalmology Glaucoma, May 2026
Authors: Williams et al.
Using natural language processing to analyze 221,378 glaucoma clinic notes from 6,452 patients, investigators found that nearly three-quarters of patients returned later than their physician-recommended follow-up interval at least once, with Black and Hispanic patients at particularly high risk for lapses in care. This study highlights how AI-based review of free-text clinic notes could help practices identify overdue glaucoma patients based on individualized follow-up recommendations rather than arbitrary time cutoffs, although the retrospective single-center design, reliance on ICD coding and imperfect NLP extraction, and lack of correlation with actual glaucoma progression limit conclusions about which delays are most clinically significant.
FDA clears wireless negative-pressure goggles that let practices track overnight use in adults with glaucoma.
SpyGlass Pharma’s bimatoprost-IOL system receives an add-on Category III CPT Code as Phase 3 development continues.
Illinois Tech reports a third wireless visual cortex prosthesis implantation with 34 stimulators and 544 electrodes.
Biogen closes $5.6B acquisition of Apellis, adding SYFOVRE for geographic atrophy and EMPAVELI for rare kidney diseases.
In 1876, Louis de Wecker created one of the first glaucoma drainage shunts using what material?
A. Silk thread
B. Gold wire
C. Horsehair
D. Rubber tubing
See answer at bottom of newsletter
Get the next issue in your inbox
The Open Angle is a weekly glaucoma research newsletter for busy eye care professionals.
Four papers worth knowing, in under four minutes.
Edited by Jella An, MD, MBA and Jason Dossantos, MD.
The Open Angle is an educational editorial product. It is not medical advice. Readers should review original sources before changing practice.
Trivia Answer: B